Drug profile

The FDA adverse-event record for Ophiopogon Japonicus Root Extract

63 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Ophiopogon Japonicus Root Extract. See the species affected, top reactions, and outcomes below.

63
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
19
Application site erythema - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
63
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Ophiopogon Japonicus Root Extract

Administration Routes

TopicalUnknown

Species Affected

Dog 51
Cat 9
Human 3

Most Affected Breeds

Crossbred Canine/dog 7
Shih Tzu 5
Terrier - Yorkshire 4
Dog (unknown) 4
Sphynx 3
Unknown 3
Pit Bull 3
Bulldog - French 2
Domestic (unspecified) 2
Domestic Shorthair 2

Most Reported Reactions

Application site erythema 19
Application site pruritus 9
Lack of efficacy - NOS 7
Flaking skin 4
Application site irritation 4
Pruritus 4
Hives (see also 'Skin') 3
Urinary tract infection 2
Moist dermatitis 2
Application site blister 2
Odor, Abnormal 2
Application site itching 2

Outcome Breakdown

Ongoing
23 (36.5%)
Recovered/Normal
23 (36.5%)
Outcome Unknown
17 (27.0%)

Ophiopogon Japonicus Root Extract Adverse Event Insights

63 reports name Ophiopogon Japonicus Root Extract; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Ophiopogon Japonicus Root Extract. Administration routes: Topical, Unknown.

By species: Dog (51 reports), Cat (9 reports), Human (3 reports). By breed: Crossbred Canine/dog (7), Shih Tzu (5), Terrier - Yorkshire (4).

Leading clinical signs: Application site erythema (19), Application site pruritus (9), Lack of efficacy - NOS (7), Flaking skin (4). Outcome, 63 coded reports: Ongoing leads at 36.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.